Santen Pharmaceutical Co. is eyeing the North American market and planning to launch products for glaucoma and retina disease, Shigeo Taniuchi, president and chief operating officer, said at the 37th annual J.P. Morgan Healthcare Conference.
The company has targeted launches planned in the coming years for its glaucoma products DE-117, DE-126 and DE-128, as well as DE-109 and DE-122 for retinal diseases.
“In order to manage glaucoma treatment, it is very important and essential to have a wide variety of products for a tailor-made approach for each patient,” Taniuchi said. “This
Uncategorized